We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Home Test Confirms Men's Post-Vasectomy Sterility

By Labmedica staff writers
Posted on 19 Mar 2008
Vasectomies are not 100% effective, and vasectomized men can experience recanalization, or the spontaneous healing or restoration of the vas deferens resulting in fertility. More...
A test has been developed that can be used to monitor and confirm sterility following the vasectomy procedure, alerting couples should fertility become restored. In addition, the device could be used to monitor male infertility over time in the event that male contraceptive pills are successfully developed.

The device gives men an opportunity to test their post vasectomy fertility status at home rather than return to the physician's office or a laboratory with semen samples, as has traditionally been required to confirm sub-fertile sperm levels.

A gene (ACRV1) was identified that encoded a protein that could serve as a sperm-specific biomarker. The SP-10 protein is very soluble and highly expressed, making it an ideal target for diagnostic testing. The new device uses monoclonal antibodies that bind specifically to the SP-10 protein to measure the amount in nanograms of SP-10 protein, which directly correlates to the number of sperm present.

Called SpermCheck Vasectomy, the test was created using technology developed by Professor John C. Herr, director of University of Virginia's Center for Research in Contraceptive and Reproductive Health (Charlottesville, VA, USA). The test been approved by the U.S. Food and Drug Association (FDA; Rockville, MD, USA).

"The SpermCheck Vasectomy test is the result of many years of basic science research coupled with clinical chemistry know-how,” said Prof. Herr. "Similar to a home pregnancy test for women, it is the first immunodiagnostic test with the sensitivity and specificity required to detect low numbers of sperm, and it is the first immunodiagnostic test to receive FDA approval for monitoring sperm count after vasectomy.”


Related Links:
U.S. Food and Drug Association
University of Virginia's Center for Research in Contraceptive and Reproductive Health

Gold Member
Flocked Fiber Swabs
Puritan® Patented HydraFlock®
New
Gold Member
Neonatal Heel Incision Device
Tenderfoot
New
Electrolyte Analyzer
CBS-4000 (CBS-400)
New
Thyroid Test
Anti-Thyroid EIA Test
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image

Urine-Based Multi-Cancer Screening Test Receives FDA Breakthrough Device Designation

Early detection across multiple cancers remains a major unmet need in population screening. Non-invasive approaches that can be delivered at scale may broaden access and shift diagnoses to earlier stages.... Read more

Molecular Diagnostics

view channel
Image: The new approach focuses on CpG DNA methylation, a chemical modification of cytosine and guanine bases, using tumor samples to develop a computational model that distinguishes among 21 cancer types (photo credet: 123RF)

Machine Learning Model Uses DNA Methylation to Predict Tumor Origin in Cancers of Unknown Primary

Cancers of unknown primary (CUP) are metastatic malignancies in which the primary site cannot be identified, complicating treatment selection. Many patients consequently receive broad, nonspecific chemotherapy... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.